Multiple Sclerosis
Multiple sclerosis (MS) is a condition characterized by the destruction of areas of myelin, the fatty covering that surrounds the nerve fibers in the spinal cord. The spinal cord is like an electrical line that carries nerve signals to/from the brain and body. When an area of myelin is damaged, the nerve signals can “short-circuit” (like a break in an electrical cord) and communication is disrupted. Myelin destruction occurs when the body’s immune system mistakenly attacks its own tissue. However, the exact trigger for this process is unknown.

According to the Multiple Sclerosis Association of America, about 400,000 Americans have MS and 10,000 new cases are diagnosed every year. Women are affected about three times more often than men. The condition can occur at any age, but most patients are between 16 and 60 when they are diagnosed.

Fampridine for Mobility
Andrew Goodman, M.D., Neurologist with the University of Rochester Medical Center, says one of the most common impairments associated with MS is trouble walking, caused by weakness, fatigue and troubles with coordination and balance. Researchers are testing a medication that may greatly improve walking ability in patients with MS. The drug is called Fampridine-SR (also known as 4-aminopyridine).

When myelin is damaged, electrically charged particles, called potassium ions, leak out through channels in the axon (the nerve extension). The leaking ions causes the nerve’s electrical current to dissipate, short circuiting the signals and disrupting nerve communication. According to the manufacturer (Acorda® Therapeutics), Fampridine-SR closes off the exposed potassium channels. This keeps the potassium ions from leaking out and allows the nerve signals to travel uninterrupted through damaged areas of myelin.

Fampridine is an oral medication that’s taken two times a day. In a phase III study, researchers randomly assigned more than 300 patients to receive either Fampridine or a placebo for 14 weeks. The investigators found 35 percent of those taking Fampridine had a significant improvement in their walking ability versus 8 percent of those taking a placebo. The results were published in the February 28, 2009 issue of The Lancet.

Goodman says Fampridine is designed to be used after the myelin has already been damaged. There is no proof the drug will prevent future damage. If the medication is stopped, the symptoms will return.

Acorda® Therapeutics has filed a new drug application with the FDA and has received a Priority Review status. The FDA is expected to make an approval decision for the drug by early next year.

AUDIENCE INQUIRY

For information about Fampridine-SR, go to http://www.acorda.com

For information on multiple sclerosis:
Multiple Sclerosis Association of America, http://www.msassociation.org
Multiple Sclerosis Foundation, http://www.msfocus.org
National Institute of Neurological Disorders and Stroke, http://www.ninds.nih.gov
National Multiple Sclerosis Society, http://www.nationalmssociety.org

Research compiled and edited by Barbara J. Fister

© 2009 Medstar Television, Inc. All Rights Reserved
 

 Subscribe RSS

  Bookmarks  Email This   Hits : 1517

Trackback ( 0 )
Trackback Link for This Article

Comments (0)

Your Comment

Name* Email* Website Title* UBBCode B i u Quote Code List List item Img URL Comment*   0 Characters Verify Code*    Notify me when new comment post on this article.  I have read and agree to Term and Agreement By submitting your comments ABC 36 we reserve the right, at our sole discretion, delete, or deny approval of your comments for any reason at any time without further notice. We do not rent, sell, or exchange your name, personal information, or email address to third-party companies for their marketing purposes. Please allow up to 24 hours for your post to be approved. Thanks from ABC 36 for your comment on our site wtvq.com